Friday, June 13, 2014

4 of the top 10 highest paid CEOs are in Medical Supplies or Drugs.

Catching Hepatitis: Why Merck (MRK) Was Willing to Break the Bank for Idenix (IDIX) 

Sovaldi Has Demonstrated Treating Hepatitis C is a Good Business to Be In

Idenix has zero, count ‘em, zero therapies that are currently commercially available and had zero, count ‘em, zero dollars in revenue last year. So why the massive price tag for a company whose most-advanced therapy has only reached Phase II clinical trials? Because the company’s primary focus is treating hepatitis C, a market that has grown astonishingly lucrative and is getting astonishingly competitive as a result. ISI Group analyst Mark Schoenebaum said in a research note the price paid by Merck would place the global hepatitis C market at $20 billion by 2018, and everyone's now fighting to secure their piece.
The first inklings that this would be the case came when Gilead Sciences (GILD) announced that Sovaldi, the first truly effective hepatitis C treatment to hit the market, would cost $84,000 for a round of treatment, better than $1,000 a pill.
This created waves. Big ones. Henry Waxman fired off a strongly-worded letter to Gilead CEO Dr. John C. Martin ...


Click photos for larger size

 John C. Martin, Gilead Sciences #10 recently moved to #1 

 Stephen Hemsley, United Health Group

 John Hammergreen, McKesson Medical Supplies

John Hammergreen, McKesson Medical Supplies


VA puts Gilead's $1,000-a-pill hepatitis C drug on its list of meds


Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi


Is this Gilead's Biggest Risk?

Motley Fool - ‎22 minutes ago‎
In fact, Sovaldi poses a huge riddle for Gilead. How can a $1,000 pill designed overwhelmingly for those who are low-income, or live in low- income countries, become accessible to the patients who need it most? In the United States, more than half of the ... In the near term, Gilead faces a risk doctors may choose to wait to treat hepatitis C patients until later in 2014, when the fixed-dose combination Sovaldi + Ledipasvir becomes available. At the very least, the need to find all those new patients each quarter will make ... 

AHF Supports AHIP's Labeling of Sovaldi Pricing as “Unsustainable,” Reaffirms ...

MarketWatch - ‎Jun 12, 2014‎
WASHINGTON, Jun 12, 2014 (BUSINESS WIRE) -- In a series of letters to be sent to state Medicaid directors this week, AIDS Healthcare Foundation (AHF) President Michael Weinstein will ask the state directors to block Gilead Sciences' new $1,000-per-pill ... 

Govt urged to make new hepatitis drug affordable - ‎20 hours ago‎
Sovaldi, whose developer, Gilead, an American pharmaceutical company, is expected to earn $9.1 billion by 2017, was recently registered by the US Food and Drug Administration. However, it has yet to be registered in Pakistan. ... According to Professor Najib, the cost of Sovadi is $1,000 per tablet in the US and that the high price forced local insurance companies to have reservations about its coverage in the health insurance schemes and thus, restricting its prescription. “Unfortunately, the laws of the potency of ...

Health: No sofosbuvir patent in Egypt, but Gilead deal still expensive
Cairo, 8 April (Heba Wanis*) – Preliminary examination of the patent application on sofosbuvir, a major hepatitis C medicine, at the Egyptian Patent Office showed that it is unlikely to be patented. 

India’s pro-consumer patent regime is an exciting alternative to the dominant IP model pushed by the US

Gilead’s Sovaldi is a wonder drug sold at a shocker price. It is the most effective cure for Hepatitis C, and is in high demand. But the drug has caused an outrage in the US where patients, healthcare providers and insurers have questioned its exorbitant price tag. For a 12-week course, Sovaldi costs $84,000 (₹50,00,000). 

Sovaldi was also in the news for an entirely different set of reasons. Earlier this month, an Indian generic firm, Natco, filed a ‘pre-grant opposition’ to Gilead’s patent covering Sovaldi. The move could result in the Indian Patent Office rejecting Gilead’s patent, bringing down the price to a fraction of its current price.

This is not a one-off incident. India has tackled the issue of unaffordable prices of drugs protected by patents by incorporating a remarkable array of provisions into its intellectual property (IP) law. 

These provisions qualify as ‘legitimate flexibilities’ allowed under the WTO’s Trade Related aspects of Intellectual Property Rights (TRIPS) Agreement. ...

At $1000 per pill, Gilead's hepatitis C drug has insurers, others ...

San Francisco Business Times (blog)-May 30, 2014
Drug manufacturer Gilead Sciences defends the price tag on grounds ... over a 10-to-30-year span, leading to cirrhosis, liver failure and death. ...

Hepatitis C drugs show promise, but price is too high for most patients

CTV News-May 25, 2014
In an email to CTV News, Gilead, the makers of Sovaldi, said that the ... sugar-coat her reality: "I am stage 4, the next step is death," she said. you know there is a cure for Hepatitis C but we may never see it?
  • Over 170 million people worldwide have the virus, 4 million people in the U.S.
  • Hepatitis C (HCV) now kills more people than AIDS
  • Liver Cancer due to Hepatitis C is the most rapidly increasing cause of cancer death in the U.S.
  • HCV is the number one reason for liver transplants
  • 3-4% of adults are chronically infected
What can you do to help?
Act NOW and sign the petition to pressure Gilead Sciences to work with Bristol-Myers on the Phase III drug trials necessary to get the cure to market.

1980 Forest View Avenue
    Hillsborough, CA 94010
Find on map >>
Show street view
Land value: $1,671,831
Building value: $1,671,831
Total value for property: $3,343,662
Assessments for tax year: 2009
Last sale: $2,650,000
Date of last sale: 06/13/1997

  1. Rosemary Martin - $7,600 in Political Contributions for 2004
    HILLSBOROUGH, CA 94010, None/None, $5,000, 07/12/2004, P, GILEAD SCIENCES INC HEALTHCARE POLICY PAC · Martin, Rosemary A Mrs. PEARLAND ...
  2. Rosemary Martin - $5,000 in Political Contributions for 2006
    ... Contibuted To. Martin, Rosemary HILLSBOROUGH, CA 94010, Homemaker, $5,000, 01/11/2006, P, GILEAD SCIENCES INC HEALTHCARE POLICY PAC ...
  3. HILLSBOROUGH, California (CA) Political Contributions by ...
    Latest news about elections in HILLSBOROUGH, CA collected exclusively by ...... Rosemary Martin (Homemaker), (Zip code: 94010) $5000 to GILEAD ...
  4. HILLSBOROUGH, California (CA) Political Contributions by ...
    FCC Registered Amateur Radio Licenses in city_name, California. ... Rosemary Martin (None/None), (Zip code: 94010) $5000 to GILEAD SCIENCES INC ...
  5. **Obituaries** - Florida Times-Union
    The Florida Times‑Union
    Nov 21, 2000 - She is survived by her husband, Dr. Tellis A. Martin; four children; Dr. John C. (Rosemary) Martin of Hillsborough, CA, Carolyn L. (Thomas) ...

    MARTIN - Janet Sacks Martin, 72, passed away on Saturday, November 18, 2000. She was born on January 11, 1928 in Philadelphia, PA. She graduated from Ursinus College in Collegeville, PA with a B. S. in Chemistry in 1949. Jan moved with her family to Evansville, Indiana in 1953. After graduating from the University of Evansville with a Masters in Education, she taught chemistry, physics and computer literacy at the Evansville Day School for move than twenty years. She relocated to Isle of Palms, SC after retirement in 1987 where she was an elder of the Sunrise Presbyterian Church, and active in the Garden Club, the Newcomers Club, the Literacy Program of Charleston and was a volunteer Medicare claims filer. In 1996 she moved to Penny Retirement Community in Penny Farms, FL, but continued to Summer in Isle of Palms. At PRC, she was Treasurer of the PRC Association and a volunteer AARP tax preparer. Jan will be remembered as a loving daughter, wife, mother and grandmother, an excellent bridge player and a good and generous friend to many. She is survived by her husband, Dr. Tellis A. Martin; four children; Dr. John C. (Rosemary) Martin of Hillsborough, CA, Carolyn L. (Thomas) Marino of New York City, Dr. Robert Sacks (Rebecca) Martin of Pacific Palisades, CA and Thomas E. (Sue Ann) Martin, CPA of Concord, NJ; and seven grandchildren, John, Margaret Rose, Noah, Rachel, Chelsea, Kelly and Robert. A Graveside memorial service will be held at 10:'30 Am on Saturday, December 2, at Penny Farms Cemetery. Memorial donations in Janets memory may be made to Penny Retirement Community, Janet Martin Memorial Fund, Box 555, Penny Farms, FL 32079.

Sue Ann Martin

John C. Martin, Ph.D., joined Gilead Sciences in 1990 and currently serves as chairman of the board of directors and CEO. Prior to joining Gilead, Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corp.
Martin has served as president of the International Society for Antiviral Research, chairman of the board of directors of BayBio and chairman of the California Healthcare Institute. He also served on the National Institute of Allergy & Infectious Diseases Council, on the board of directors of the Biotechnology Industry Organization (BIO), on the board of trustees of the University of Chicago and on the board of trustees of the Golden Gate University. Additionally, Martin served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. He is currently a member of the board at Gen-Probe Inc. He has been a member of the board of directors of CHI since 2003 and previously served as chairman of the board from 2005 to 2006 and 2009.

Hosea 6:8:  

"Gilead is a city of those who work iniquity; it is stained with blood."

Current Addresss:
Current Phone:
Possible Relatives
Thomas Martin in Concord, NH
 Current Phone:
Current Phone:
  • John C. Martin, PhD

    Chairman and Chief Executive Officer, Gilead Sciences
  • John F. Cogan, PhD

    Lead Independent Director, Gilead Sciences
  • Etienne F. Davignon

    Minister of State for Belgium, Chairman, Genfina
  • Carla A. Hills

    Chair and Chief Executive Officer, Hills & Company, International Consultants
  • Kevin E. Lofton

    President and Chief Executive Officer, Catholic Health Initiatives
  • John W. Madigan

    Retired Chairman and Chief Executive Officer, Tribune Company
  • Nicholas G. Moore

    Retired Global Chairman, PricewaterhouseCoopers
  • George P. Shultz, PhD

    Director Emeritus, Gilead Sciences
  • Richard J. Whitley, MD

    Distinguished Professor, Loeb Scholar Chair in Pediatrics, Professor of Pediatrics, Microbiology, Medicine, and Neurosurgery, University of Alabama at Birmingham
  • Gayle Edlund Wilson

    Immediate Past Chair, Ralph M. Parsons Foundation
  • Per Wold-Olsen

    Retired President, Human Health Intercontinental Division, Merck & Co., Inc.


No comments:

Post a Comment